Jettie J.F. Muris

Integration of genomic, transcriptomic and proteomic data identifies two biologically distinct subtypes of invasive lobular breast cancer

Magali Michaut, Suet‐Feung Chin, Ian J. Majewski et al. · Scientific Reports · 2016 · 179 citations · Full text

Medicine, Molecular Biology, Oncology +17

Expression of the granzyme B inhibitor, protease inhibitor 9, by tumor cells in patients with non-Hodgkin and Hodgkin lymphoma: a novel protective mechanism for tumor cells to circumvent the immune system?

Bellinda A. Bladergroen, Chris J.L.M. Meijer, Rosita L. ten Berge et al. · Blood · 2002 · 154 citations · Full text

Medicine, Immunology, Oncology +17

Prognostic significance of activated cytotoxic T-lymphocytes in primary nodal diffuse large B-cell lymphomas

Jettie J.F. Muris, C J Meijer, Saskia A.G.M. Cillessen et al. · Leukemia · 2003 · 97 citations

Medicine, Oncology, Pathology +10

Expression of the Apoptosis Inhibitor Protease Inhibitor 9 Predicts Clinical Outcome in Vaccinated Patients with Stage III and IV Melanoma

Inge S. van Houdt, Joost J. Oudejans, Alfonsus Johannes Maria van den Eertwegh et al. · Clinical Cancer Research · 2005 · 90 citations · Full text

Life Sciences, Immunology, Oncology +17

Immunohistochemical profiling of caspase signaling pathways predicts clinical response to chemotherapy in primary nodal diffuse large B-cell lymphomas

Jettie J.F. Muris, Saskia A.G.M. Cillessen, Wim Vos et al. · Blood · 2004 · 84 citations · Full text

Medicine, Oncology, Pathology +11